## FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPRO\	/AL
	3235-0287
Estimated average bu	rden
hours per response	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	es)													
1. Name and Address of Reporting Person * GOLDSTEIN JACK  (Last) (First) (Middle) 1522 217TH PLACE SE, SUITE 100				2. Issuer Name and Ticker or Trading Symbol ONCOGENEX PHARMACEUTICALS, INC. [OGXI]					_X_ Dire		eck all appli	cable) _ 10% Ow			
			3. Date of Earliest Transaction (Month/Day/Year) 06/08/2010												
(Street)				4. If Amendment, Date Original Filed(Month/Day/Year)					6. Individual or Joint/Group Filing(Check Applicable Line) Form filed by One Reporting Person Form filed by More than One Reporting Person						
BOTHELL, WA 98021 (City) (State) (Zip)			(Zip)	Table I - Non-Derivative Securities Acqu					ties Acqu	uired, Disposed of, or Beneficially Owned					
1.Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year)		n Date, i	Code (Inst	e	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		5. Amount of Securities B Owned Following Reporte Transaction(s)			Owr	nership of m: Be	7. Nature of Indirect Beneficial
				(Month/I	Day/Year		ode V	Amount (D)		(Instr. 3 and 4)			Direct (D) Ownersh or Indirect (I) (Instr. 4)		
Reminder:							conta	ns who resp ined in this f displays a cu	orm are i	not requ	red to resp	ond unless	the	SEC 11	74 (9-02)
Reminder:													the	SEC 11	74 (7-02)
1. Title of	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Date, if	4. Transac Code	5. tion Num of Der Sec	arran	conta form of equired, Dis ts, options, of 6. Date Exc Expiration (Month/Da	ined in this fidisplays a cuposed of, or Beconvertible securicable and Date	eneficially eurities)  7. Title of Under Securiti	not requivalid OMI y Owned and Amoerlying	red to resp 3 control no	of 9. Numb Derivative Securitie	er of 1000 cm of 1000	10. Ownership Form of Derivative Security: Direct (D)	11. Natur of Indired Beneficia
1. Title of Derivative Security	Conversion or Exercise Price of Derivative	Date	3A. Deemed Execution Date, if any	4. Transac Code	5. tion   5. Num of   Der   Sec   (A)   Dis   of (Ins	arran  ivative urities uired or oosed	conta form of equired, Dis ts, options, of 6. Date Exc Expiration (Month/Da	ined in this fidisplays a cuposed of, or Beconvertible securicable and Date	eneficially eurities)  7. Title of Under Securiti	not requivalid OMI y Owned and Amoerlying ies	unt 8. Price Derivati	ond unless imber.  of 9. Numb ve Derivativ Securitie Beneficia Owned	er of 1 ve ( ss H shlly I ss I s	10. Ownership Form of Derivative Security:	11. Natur of Indirec Beneficia Ownersh
1. Title of Derivative Security	Conversion or Exercise Price of Derivative	Date	3A. Deemed Execution Date, if any	4. Transac Code	5. tion   5. Num of   Der   Sec   (A)   Dis   of (Ins	nber ivative urities uired or posed D) tr. 3, nd 5)	conta form of course of the co	ined in this fidisplays a cuposed of, or Beonvertible seem in the	eneficially eurities)  7. Title of Under Securiti	not requivalid OMI y Owned and Amoerlying ies	unt 8. Price Derivati Security (Instr. 5	of 9. Numb ve Derivativ Securitie Owned Followin Reported Transact	er of 1 ve ( ss H shlly I ss I s	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)	11. Natur of Indired Beneficia Ownersh

#### **Reporting Owners**

P 4 0 Y 4	Relationships				
Reporting Owner Name / Address	Director	10% Owner	Officer	Other	
GOLDSTEIN JACK 1522 217TH PLACE SE SUITE 100 BOTHELL, WA 98021	X				

### **Signatures**

Sandra Thomson as attorney-in-fact for Jack Goldstein	06/09/2010
**Signature of Reporting Person	Date

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The options shall vest in full on the earlier of June 8, 2011 or the date immediately prior to Oncogenex Pharmaceuticals, Inc.'s next annual meeting of

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.